-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
6667px;'> On March 4 and March 5, 2021, the Fourth Session of the Thirteenth National People's Congress and the Fourth Session of the Thirteenth National Committee of the Chinese People's Political Consultative Conference will open in Beijing respectively.
6667px;'> Innovative R&D
Innovative R&D6667px;'> Sun Piaoyang, Chairman of Hengrui Pharmaceuticals
Sun Piaoyang, Chairman of Hengrui Pharmaceuticals6667px;'> Solve the excessive duplication of innovative drugs and simplify the process of drug negotiation
Solve the excessive duplication of innovative drugs and simplify the process of drug negotiation6667px;'> It is recommended to use top-level design policy guidance, including medical insurance, access, etc.
6667px;'> Chen Baohua, President of Huahai Pharmaceutical
Chen Baohua, President of Huahai Pharmaceutical6667px;'> Improve the "patent link" system
Improve the "patent link" system6667px;'> Speed up the establishment and improvement of my country's drug "patent link" system: speed up the revision and improvement of the "China Listed Drug Catalogue"; improve the "patent period compensation" system; improve the first generic drug "market exclusivity period" system; establish a "simplified new drug application" system ; Clearly stipulate the scope of "first imitation date" and "first imitation person"; establish a patent linkage mechanism to ensure the implementation of the patent linkage system, and play a "pull" role in the use link and a "guarantee" promotion role in the supervision link.
6667px;'> Dai Lizhong, Chairman of Shengxiang Biological
Dai Lizhong, Chairman of Shengxiang Biological6667px;'> Create internationally competitive leading products and leading enterprises
Create internationally competitive leading products and leading enterprises6667px;'> During the "14th Five-Year Plan" period, high-quality development of the pharmaceutical industry should be promoted, leading biomedical companies with strong innovation capabilities should be actively supported, and leading products and leading companies with international competitiveness should be created.
6667px;'> biomedicine
biomedicine6667px;'> Li Yan, President of Qilu Pharmaceutical
Li Yan, President of Qilu Pharmaceutical6667px;'> Strengthen the top-level design of the biomedical industry and encourage domestic substitution
Strengthen the top-level design of the biomedical industry and encourage domestic substitution6667px;'> Promulgate top-level policies specifically to support the development of the biomedical industry as soon as possible, open up new drug project approval, approval, production, and use links, focus on solving problems such as slow approval and review, and difficulty in admitting drugs to hospitals, and encourage and support those who are in the forefront of the world and are at the forefront of global technology.
6667px;'> Wang Weidong, Chairman of Rongchang Pharmaceutical
Wang Weidong, Chairman of Rongchang Pharmaceutical6667px;'> Cancel the time limit for bio-innovative drugs to participate in national medical insurance negotiations
Cancel the time limit for bio-innovative drugs to participate in national medical insurance negotiations6667px;'> Pay attention to the transformation and industrialization of biomedical science and technology innovation achievements, and realize the realization of industrialization.
6667px;'> Chinese medicine
Chinese medicine6667px;'> Lu Qingguo, Chairman of Chenguang Bio
Lu Qingguo, Chairman of Chenguang Bio6667px;'> Speed up the pace of Chinese patent medicines entering the centralized drug procurement
Speed up the pace of Chinese patent medicines entering the centralized drug procurement6667px;'> It is recommended to create conditions as soon as possible to allow proprietary Chinese medicines to enter the mechanism of centralized drug procurement bidding, so that more traditional Chinese medicine manufacturers can participate in the competition fairly; improve the standard system, include traditional Chinese medicine formula granules into the drug centralized bidding procurement system, and promote the development of traditional Chinese medicine formula granules.
6667px;'> Xiao Wei, Chairman of Jiangsu Kangyuan
6667px;'> Establish a centralized procurement model that meets the characteristics of Chinese medicine
6667px;'> Combining with the actual development of Chinese medicine, establish a centralized purchasing management model that meets the complex characteristics and unique attributes of Chinese medicine, and formulate a centralized purchasing policy of "classification + generic name".
6667px;'> other
other6667px;'> Yu Qingming, Chairman of Sinopharm Holdings
Yu Qingming, Chairman of Sinopharm Holdings6667px;'> Establish a sound medical logistics standard system
Establish a sound medical logistics standard system6667px;'> It is recommended to formulate unified standards for third-party logistics access and warehouse establishment of drugs in different places to solve the problem of inconsistency in regional pharmaceutical logistics policies.
6667px;'> Yuan Yafei, Chairman of Sanpower Group
Yuan Yafei, Chairman of Sanpower Group6667px;'> Establish a digital three-medicine linkage tool to promote resource collaboration
Establish a digital three-medicine linkage tool to promote resource collaboration6667px;'> Deepen the reform of the three-medicine linkage.
6667px;'> Feng Danlong, Senior Consultant of Pfizer Pharmaceuticals China Corporate Affairs Department
Feng Danlong, Senior Consultant of Pfizer Pharmaceuticals China Corporate Affairs Department6667px;'> Promote the construction of commercial insurance
Promote the construction of commercial insurance6667px;'> It is recommended to accelerate the establishment of a national-level commercial insurance information sharing and support platform, strengthen guidance and standard management, and at the same time encourage the government at the system and policy level to promote the realization of "subtraction" in supervision work, and in the improvement of support and services.
6667px;'> Attached:
6667px;'> List of medical representatives from the two sessions in 2021
